Monday, 20 January 2020

GSK appoints Kevin Sin as SVP, Global Research Head

20 April 2018 | News

Kevin will join GSK in July 2018 from Genentech, where he is currently Vice President and Global Head of Oncology Business Development.

Image credit- cityam.com

Image credit- cityam.com

GlaxoSmithKline (GSK) has announced the appointment of Kevin Sin as Senior Vice President and Head of Worldwide Business Development for Pharmaceuticals Research & Development. In this position, Kevin will play a critical role in strengthening GSK’s pharmaceutical pipeline and identifying enabling technologies to enhance delivery of innovative new medicines for patients. 

Kevin will join GSK in July 2018 from Genentech, where he is currently Vice President and Global Head of Oncology Business Development, responsible for partnering, acquisition and licensing activities for novel oncology therapeutics. 

He has worked within the pharmaceutical and life sciences industry for over 20 years in roles spanning business development, legal and research. Prior to joining Genentech in 2006, Kevin was an attorney advising private and public life sciences companies on business development and strategic partnering transactions. He began his career as a scientist.

Kevin holds a B.A. in Molecular and Cell Biology from the University of California, Berkeley and a post graduate degree (Juris Doctor) from the University of San Francisco School of Law.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is 2020 demanding timely action of technology adoption in healthcare?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls